Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells

Cancer Letters
Inna ZubrilovIsaac P Witz

Abstract

V600E being the most common mutation in BRAF, leads to constitutive activation of the MAPK signaling pathway. The majority of V600E BRAF positive melanoma patients treated with the BRAF inhibitor vemurafenib showed initial good clinical responses but relapsed due to acquired resistance to the drug. The aim of the present study was to identify possible biomarkers associated with the emergence of drug resistant melanoma cells. To this end we analyzed the differential gene expression of vemurafenib-sensitive and vemurafenib resistant brain and lung metastasizing melanoma cells. The major finding of this study is that the in vitro induction of vemurafenib resistance in melanoma cells is associated with an increased malignancy phenotype of these cells. Resistant cells expressed higher levels of genes coding for cancer stem cell markers (JARID1B, CD271 and Fibronectin) as well as genes involved in drug resistance (ABCG2), cell invasion and promotion of metastasis (MMP-1 and MMP-2). We also showed that drug-resistant melanoma cells adhere better to and transmigrate more efficiently through lung endothelial cells than drug-sensitive cells. The former cells also alter their microenvironment in a different manner from that of drug-sensit...Continue Reading

References

Jul 13, 2001·The Journal of Cell Biology·R A WorthylakeK Burridge
Dec 4, 2001·Biology of the Cell·C Peyssonnaux, A Eychène
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Sep 6, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·B B WekslerP O Couraud
Mar 15, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ron N ApteElena Voronov
Sep 6, 2007·Cancer Metastasis Reviews·Emmanouil FokasHan-Xiang An
Sep 25, 2007·Clinical & Experimental Metastasis·Stéphanie GoutJacques Huot
Sep 25, 2007·Clinical & Experimental Metastasis·Adit Ben-Baruch
Jun 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine E Eyler, Jeremy N Rich
Oct 1, 2008·Gynecologic Oncology·Antonio SorrentinoCristiano Ferlini
Nov 13, 2008·Cytotechnology·Gail M Seigel, Lorrie M Campbell
Aug 25, 2009·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Isaac P Witz
Dec 17, 2009·Immunology Letters·Sivan IzraelyIsaac P Witz
Jan 26, 2010·International Journal of Cancer. Journal International Du Cancer·Olga KholmanskikhEtienne De Plaen
Jun 16, 2010·Pigment Cell & Melanoma Research·Matthew Held, Marcus Bosenberg
Apr 8, 2011·Current Pharmaceutical Biotechnology·M J CarliniL Puricelli
Apr 22, 2011·Nature Reviews. Cancer·Prathibha RanganathanAnthony J Capobianco
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Oct 26, 2011·International Journal of Cancer. Journal International Du Cancer·Sivan IzraelyIsaac P Witz
Nov 16, 2011·Current Molecular Medicine·M GarofaloG Condorelli
Mar 27, 2012·Expert Opinion on Therapeutic Targets·Alice ZoccoliDaniele Santini
Mar 27, 2012·International Journal of Cancer. Journal International Du Cancer·Anat KleinIsaac P Witz
Oct 2, 2012·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Virginia TirinoGianpaolo Papaccio
Jan 8, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ryan J Sullivan, Keith T Flaherty
Feb 27, 2013·Experimental Cell Research·Anja Irmisch, Joerg Huelsken
Jul 25, 2013·Advanced Drug Delivery Reviews·Arun K IyerMansoor M Amiji
Aug 21, 2013·Advanced Drug Delivery Reviews·Yoav D Livney, Yehuda G Assaraf
Aug 31, 2013·Cancer Letters·Anat Klein-GoldbergIsaac P Witz
Sep 7, 2013·Frontiers in Oncology·Anshul AwasthiJoel D A Tyndall
Sep 13, 2013·The Journal of Pathology·Blanca Homet, Antoni Ribas
Oct 15, 2013·Advanced Drug Delivery Reviews·Janet L MarkmanJulia Y Ljubimova
Feb 14, 2014·Pharmacogenomics and Personalized Medicine·Kohji NoguchiYoshikazu Sugimoto
Mar 4, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Outi Itkonen, Ulf-Håkan Stenman
Apr 16, 2014·Frontiers in Physiology·Elena VoronovRon N Apte
Apr 30, 2014·Journal of Experimental & Clinical Cancer Research : CR·Evandro Luís NieroGláucia Maria Machado-Santelli
May 27, 2014·Cell Reports·Jean AlbrenguesCedric Gaggioli
Jun 3, 2014·Breast Cancer Research : BCR·Helena AguilarMiguel Angel Pujana
Jun 7, 2014·Molecular Cell·Hariharan EaswaranStephen B Baylin
Jun 24, 2014·Seminars in Cancer Biology·Monica CojocAnna Dubrovska

❮ Previous
Next ❯

Citations

Mar 30, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alexander RoeschDirk Schadendorf
Jun 29, 2016·Biochemical Pharmacology·Michael F EmmonsKeiran S M Smalley
Jul 12, 2018·International Journal of Cancer. Journal International Du Cancer·Sivan IzraelyIsaac P Witz
Apr 19, 2017·Oncotarget·Anat KleinIsaac P Witz
Nov 5, 2017·Oncotarget·Sivan IzraelyIsaac P Witz
Nov 9, 2016·Melanoma Research·Alexey A LeontovichUNKNOWN Melanoma Study Group of the Mayo Clinic Cancer Center
Aug 31, 2017·Scientific Reports·Josefine RadkeTorben Redmer
Feb 15, 2020·Apoptosis : an International Journal on Programmed Cell Death·Kezhu LiShifeng Jin
Aug 23, 2017·Proceedings of the National Academy of Sciences of the United States of America·Megan C DugganWilliam E Carson
Jan 10, 2017·Laboratory Investigation; a Journal of Technical Methods and Pathology·Mariusz L HartmanMalgorzata Czyz
Sep 4, 2020·Cancers·Anna Vidal, Torben Redmer
Jul 10, 2020·Cancer Research·Manuel ValienteFrank Winkler
Jan 27, 2019·Cancer Research·Hila DoronNeta Erez
Jun 4, 2017·Molecular Cancer Therapeutics·Antonio AhnMichael R Eccles
Jul 3, 2019·Seminars in Cancer Biology·Monica MarzagalliPatrizia Limonta
Feb 20, 2021·Cancer Biology & Therapy·Eric T AlexanderSusan K Gilmour

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Related Papers

The New England Journal of Medicine
Jason P Lott
The New England Journal of Medicine
Stéphane DalleLuc Thomas
The New England Journal of Medicine
Hiroyuki Morita, Ryozo Nagai
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Hans StarzChristian Haas
© 2022 Meta ULC. All rights reserved